Donald J. Santel has served as our CEO since June 2008, and has been a member of our board of directors since 2007. Mr. Santel was previously a member of the board of directors and the CEO of CoTherix, Inc., a biopharmaceutical company he cofounded in 2000. He brought CoTherix public in 2004, when he was responsible for the oversight of all aspects of the business and led the sale of the company to Actelion in 2007. Prior to joining CoTherix, Mr. Santel was employed by or consultant to several medical device companies, including Reflow Medical, Inc., Cardiac Pathways Corporation, and Medtronic, Inc. He has also served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc. and as a director of ChemGenex Pharmaceuticals, Inc.

Mr. Santel holds an MS in electrical engineering from the University of Minnesota and a BSE in biomedical engineering from Purdue University.

Jeffrey S. Farrow was named CFO in July 2010, after previously serving as our Vice President of Finance. Before joining Hyperion, Mr. Farrow was the VP of Finance at Evotec AG, a drug discovery and development company, where he was responsible for Evotec’s corporate treasury function and compliance with the Sarbanes-Oxley Act, as well as overseeing the finance and general functions of the company’s Renovis subsidiary. Mr. Farrow held various positions between 2004 and 2008, including serving as VP of Finance and Chief Accounting Officer at Renovis, Inc. While at Renovis, Mr. Farrow was a key member of the management team responsible for the merger with Evotec, as well as Renovis’ initial public offering and secondary offering. Mr. Farrow also spent 7 years working in the audit practice of KPMG LLP.

Mr. Farrow holds a BA in business administration with a concentration in corporate finance from California State University at Fullerton.

Bruce F. Scharschmidt, MD, has served as our CMO and Senior Vice President since April 2008. In the 2 years prior to joining our company, Dr. Scharschmidt served as VP of Scientific Affairs for Novartis Vaccines, where he was responsible for developing the clinical strategy for early-stage vaccines. Dr. Scharschmidt also spent 10 years working at the senior level at Chiron Corporation, including as VP and head of Clinical Development for Vaccines and Therapeutics and, most recently, as VP of Scientific Affairs in the Corporate Group. During his time as VP, Dr. Scharschmidt was involved in the strategic direction and management of key research and development programs, including vaccines, therapeutics, and blood testing. Before joining Chiron, Dr. Scharschmidt was Chief of Gastroenterology and professor of medicine at the University of California, San Francisco.

Dr. Scharschmidt received both his MD and undergraduate degree from Northwestern University as part of a 6-year honors program in medical education. Dr. Scharschmidt completed his training in internal medicine and gastroenterology at the University of California, San Francisco.

Ms. Gould will be responsible for serving as the company’s in-house legal counsel and leading public and governmental affairs activities. Ms. Gould recently served as vice president, Corporate Development and chief legal officer at 23andMe, a personal genetics company. Prior to joining 23andMe in 2007, Ms Gould was vice president, Legal Affairs at CoTherix, Inc., a biopharmaceutical company. Previously, Ms. Gould was associated with the law firms of Wilson Sonsini Goodrich & Rosati PC and O'Melveny & Myers LLP. Ms. Gould received her JD from the University of San Francisco School of Law and her B.S. in Political Economy of Natural Resources from the University of California, Berkeley.

Ms. Holles will lead Hyperion’s efforts to bring in new products to complement the existing portfolio and identify other ways to grow the company through external industry relationships. For the past five years, Ms. Holles has worked as an executive-level consultant leading business development activities for several life sciences companies. Most recently she served as executive vice president of Corporate Development for Immune Design, a leading cancer immunotherapy company based in Seattle. Ms. Holles also brings extensive in-house business development experience from KAI Pharmaceuticals, and InterMune, Inc. Ms. Holles began her career in the industry as a Marketing Planning Associate at Genentech, Inc. Ms. Holles received her M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado and her A.B. in Human Biology from Stanford University.

Christine A. Nash has served as our Senior VP and CCO since May 2012. Mrs. Nash joined us in 2007 as a senior director in marketing, later moving on to VP of Strategic Marketing and Corporate Business Development for several years. Before joining our company, Mrs. Nash held various positions at CoTherix, Inc., including most recently as Director of Marketing. In this position, Mrs. Nash led all marketing and product support aspects for the launch of the company’s initial product, Ventavis® (iloprost) Inhalation Solution. Mrs. Nash’s previous experience includes business development and product planning and management roles with GeneSoft Pharmaceuticals Inc., Oncology Therapeutics Network, Eli Lilly and Company, and Imana, Inc.

Mrs. Nash holds an MBA and a BA with honors in public policy, both from Stanford University.

Stock Quote

Price / Change



Day High:
Day Low:

4:00 PM ET on April 24, 2015
Delayed at least 20 minutes.
Provided by eSignal.